Results 191 to 200 of about 52,757 (299)

Effectiveness of contemporary treatments for iatrogenic urethral strictures following endoscopic management of benign prostatic hyperplasia: a comprehensive review. [PDF]

World J Urol
Lo Re M, Cadenar A, Pezzoli M, Fuligni E, Abbasi B, Białek Ł, Chierigo F, Frankiewicz M, Karapanos L, Klemm J, Mantica G, Neuville P, Bucca B, Oszczudłowski M, Redmond E, Scherñuk J, Tinajero JD, Verla W, Minervini A, Vetterlein MW, Cocci A, Trauma and Reconstructive Urology Working Party of the European Association of Urology Young Academic Urologists.   +21 more
europepmc   +1 more source

Isosorbide dinitrate as an effective adjunct therapy for acute urinary retention: A randomized controlled trial

BJUI Compass, Volume 7, Issue 7, July 2026.
Abstract Objective To evaluate the synergistic effect and safety of sublingual isosorbide dinitrate (ISDN) to facilitate successful voiding trial after catheterization for acute urinary retention (AUR) secondary to benign prostatic hyperplasia (BPH). Material and methods In this randomized clinical trial, male patients aged ≥ 50 years presenting with ...
Salman Soltani, Hamid Reza Ghorbani, Mahmoud Tavakkoli, Fatemeh Sadabadi, Seyyed Parham Ahmadi, Farid Zeinali   +5 more
wiley   +1 more source

Multi-Center, Real-World Registry Study of the UroLift Prostatic Urethral Lift (PUL) for Benign Prostatic Hyperplasia (BPH) in Japan. [PDF]

Int J Urol
Masumori N, Takahashi S, Anan G, Endo F, Furuta A, Haga K, Hatanaka M, Kato S, Komai Y, Kyoda Y, Matsuyama N, Murayama S, Nagamatsu H, Obinata D, Sekiguchi Z, Waseda Y.   +15 more
europepmc   +1 more source

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2162-2170, July 2026.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source

The Association Between Metabolic Syndrome and Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. [PDF]

Am J Mens Health
Gao W, Guo Y, Yu X, Zhang T, Gong H, Zhang Y.   +5 more
europepmc   +1 more source

PHLPP is neither a Phosphatase nor a Tumor Suppressor

BioEssays, Volume 48, Issue 7, July 2026.
PH domain leucine‐rich repeat protein phosphatases (PHLPP) have been described as Akt phosphatases and tumor suppressors for more than 20 years. Recent evidence, however, indicates that they are pseudophosphatases that lost catalytic activity more than 450 Mya. This article argues that new hypotheses are urgently needed to reorient the field.
Thomas A. Leonard
wiley   +1 more source

Commentary: The impact of dietary inflammation index on benign prostatic hyperplasia: insights from patient data and animal models. [PDF]

Front Nutr
Li Z, Wang L, Zhong L, Zheng D.
europepmc   +1 more source

Genetically Confirmed Osteogenesis Imperfecta (COL1A1) With Unexplained Ambiguous Genitalia in a 46,XY Child: An Index Case Report

Clinical Case Reports, Volume 14, Issue 7, July 2026.
A 6‐year‐old child with a rare dual diagnosis confirmed by genetic testing ‐ osteogenesis imperfecta (blue sclerae, disproportionate short stature) and concurrent 46,XY disorder of sex development (micropenis, hypospadias, impalpable gonads). ABSTRACT Osteogenesis imperfecta (OI) is a heritable disorder of type I collagen characterized by bone ...
Harshita Agarwal, Tathagata Jha, Mohammad Orooj Azmi, Soumita Sarkar, Vinay Suresh   +4 more
wiley   +1 more source

Benign prostatic hyperplasia to HPIN to carcinoma; the impact of mast cells and VEGF. [PDF]

Diagn Pathol
Sivrikoz ON, Eroğlu A, Öztürk B, Öztop İ, Sanal SM.   +4 more
europepmc   +1 more source

Case of Basal Cell Prostate Cancer and Recurrence With Prostatic Adenocarcinoma in a United States Military Veteran Exposed to Agent Orange

Clinical Case Reports, Volume 14, Issue 7, July 2026.
Pre‐operative and post‐operative T2 MRI and PSMA PETCT. ABSTRACT Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in men. Acinar adenocarcinoma accounts for 90% of primary prostatic cancers. Carcinoma of the basal cells of the prostate is extremely rare, making up less than 1% of prostate cancer ...
German Santiago Herrera Alzate, Piroz Bahar, Daniel S. Levin, Andrew Wood, Arvin K. George, Paul J. Chuba   +5 more
wiley   +1 more source